Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy) focused on activity, efficacy and safety

Molecular and Clinical Oncology
Ferdinando RiccardiMichele Orditura

Abstract

Exemestane (Exe) in combination with Everolimus (Eve) represents an important treatment option for patients diagnosed with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (MBC), which was previously treated with non-steroidal aromatase inhibitors (NSAI). Data from unselected populations may be useful for defining the optimal therapeutic algorithm within a clinical setting. Data from 264 HR+, HER2-MBC patients who received Exe-Eve treatment in combination, following the failure of NSAIs was retrospectively analyzed. Different lines of endocrine treatment (ET) were investigated to evaluate the efficacy and toxicity of the treatment within the 'everyday clinical practice' population. The disease control rate (DCR) was 73.1%, with no statistically significant difference among the different settings. At a median follow-up of 42 months, the median progression free survival (PFS) was 11.6, 9.7 and 7.5 months for patients treated with Exe-Eve as first, second or third line therapy, respectively. There was a statistically significant correlation with younger age, no previous adjuvant chemotherapy (CT), no previous adjuvant endocrine therapy (ET), HT duration ≥36 months,...Continue Reading

References

Nov 1, 2002·Breast Cancer Research and Treatment·William F AndersonOtis W Brawley
Jul 22, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Anne BoulayHeidi A Lane
Apr 22, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·José BaselgaHope S Rugo
Oct 5, 2010·Annual Review of Medicine·C Kent Osborne, Rachel Schiff
Dec 14, 2011·The New England Journal of Medicine·José BaselgaGabriel N Hortobagyi
Mar 13, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H S RugoH A Burris
Sep 16, 2014·International Journal of Cancer. Journal International Du Cancer·Jacques FerlayFreddie Bray
Sep 19, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M PiccartJ Baselga
Jun 2, 2015·The New England Journal of Medicine·Nicholas C TurnerUNKNOWN PALOMA3 Study Group
Jan 14, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H S RugoR Motzer
Nov 3, 2016·The New England Journal of Medicine·Gabriel N HortobagyiJoyce O'Shaughnessy
Mar 23, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F CardosoE Winer
Jun 6, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·George W SledgeAntonio Llombart-Cussac
Apr 1, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H S RugoH A Burris

❮ Previous
Next ❯

Citations

Mar 15, 2020·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·E CiruelosP Conte

❮ Previous
Next ❯

Software Mentioned

BOLERO
Statistical Package for the Social Sciences ( SPSS )
Medcalc
BRAWO
BALLET

Related Concepts

Related Feeds

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.